3,904
Participants
Start Date
December 22, 2022
Primary Completion Date
June 21, 2024
Study Completion Date
December 21, 2032
NT-proBNP
Patients will undergo an NT-proBNP which will guide their future involvement within the study. Patients with an NT-proBNP of ≥125 pg/mL will undergo transthoracic echocardiogram along with a clinical assessment - any diagnosis of HF will result in patients undergoing referral for initiation of guideline directed medical therapy (for HF).
NOT_YET_RECRUITING
Cleveland Clinic, Cleveland
NOT_YET_RECRUITING
University of British Columbia, Vancouver
NOT_YET_RECRUITING
University of Montreal, Montreal
NOT_YET_RECRUITING
Rigshospitalet, Copenhagen University Hospital, Copenhagen
NOT_YET_RECRUITING
Karolinska University Hospital, Stockholm
NOT_YET_RECRUITING
Uppsala University, Uppsala
RECRUITING
University of Glasgow, Glasgow
Collaborators (1)
University of Glasgow
OTHER
National Heart Centre Singapore
OTHER
Karolinska University Hospital
OTHER
Uppsala University
OTHER
Montreal Heart Institute
OTHER
Rigshospitalet, Denmark
OTHER
University of British Columbia
OTHER
The Cleveland Clinic
OTHER
Université de Montréal
OTHER
AstraZeneca
INDUSTRY
Roche Pharma AG
INDUSTRY
Us2.ai
UNKNOWN
NHS Greater Glasgow and Clyde
OTHER